CTNM vs. VNDA, NKTR, NATR, CRMD, INZY, MRSN, AQST, FBLG, ORGO, and VSTM
Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Vanda Pharmaceuticals (VNDA), Nektar Therapeutics (NKTR), Nature's Sunshine Products (NATR), CorMedix (CRMD), Inozyme Pharma (INZY), Mersana Therapeutics (MRSN), Aquestive Therapeutics (AQST), FibroBiologics (FBLG), Organogenesis (ORGO), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
Contineum Therapeutics (NASDAQ:CTNM) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 2 mentions for Contineum Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 0.94 beat Contineum Therapeutics' score of -1.50 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.
Vanda Pharmaceuticals has higher revenue and earnings than Contineum Therapeutics.
88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 7.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Vanda Pharmaceuticals received 531 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 68.55% of users gave Vanda Pharmaceuticals an outperform vote.
Contineum Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 80.65%. Given Contineum Therapeutics' higher possible upside, equities research analysts clearly believe Contineum Therapeutics is more favorable than Vanda Pharmaceuticals.
Contineum Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -2.75%. Contineum Therapeutics' return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.
Summary
Contineum Therapeutics and Vanda Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get Contineum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Contineum Therapeutics Competitors List
Related Companies and Tools
